Coronary artery bypass grafting without full sternotomy

Sasaki, Hideki

doi:10.1007/s00595-009-3976-y

Cited by 6 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 39 ] While MIDCAB initially mainly encompassed the revascularisation of the LAD with the LIMA, minimally invasive techniques are not restricted to patients with single-vessel disease, but can also be applied to selected cases of MVCAD. [ 5 , 40 ]…”

mentioning

confidence: 99%

Minimally Invasive Coronary Revascularisation Surgery: A Focused Review of the Available Literature

et al. 2021

View full text Add to dashboard Cite

Minimally invasive coronary revascularisation was originally developed in the mid 1990s as minimally invasive direct coronary artery bypass (MIDCAB) grafting is a less invasive approach compared to conventional coronary artery bypass grafting (CABG) to address targets in the left anterior descending coronary artery (LAD). Since then, MIDCAB has evolved with the adoption of a robotic platform and the possibility to perform multivessel bypass procedures. Minimally invasive coronary revascularisation surgery also allows for a combination between the benefits of CABG and percutaneous coronary interventions for non-LAD lesions – a hybrid approach. Hybrid coronary revascularisation results in fewer blood transfusions, shorter hospital stay, decreased ventilation times and patients return to work sooner when compared to conventional CABG. This article reviews the available literature, describes standard approaches and considers topics, such as limited access procedures, indications and patient selection, diagnostics and imaging, techniques, anastomotic devices, hybrid coronary revascularisation and outcome analysis.

show abstract

mentioning

confidence: 99%

Minimally Invasive Coronary Revascularisation Surgery: A Focused Review of the Available Literature

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The current paradigm shift towards less invasive coronary interventions are paralleled by innovative MISCAR procedural and technological advances that comply with traditional CABG principles, graft patency, clinical outcomes and patient satisfaction (63)(64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80). Various institutions and collaborative reports now describe innovative variations in robotic-and non-robotic MISCAR techniques, with reports that outline risk reduction strategies for safe implementation of MISCAR programs also emerging (115)(116)(117)(118)(119)(120)(121).…”

Section: New Developments In Minimally Invasive Surgical Coronary Art...mentioning

confidence: 99%

Minimally invasive surgical coronary artery revascularization—current status and future perspectives in an era of interventional advances

Merwe¹,

Casselman²

2023

J Vis Surg

View full text Add to dashboard Cite

We are currently witnessing rapid advances in coronary artery disease (CAD) diagnostic-and treatment technology, which include exciting developments in the utilisation of artificial intelligence, stem cell and genetic therapy and pharmacological innovation that complement contemporary transcatheter interventions (PCI) and patient preference for less invasive interventions. Progressive expansion of international CAD treatment guidelines with subsequent changes in referral patterns that favour less invasive interventions, increased patient expectations, industry driven marketing and an increasingly aging population with significant procedural risks, continue to re-define the role of conventional coronary artery bypass surgery by sternotomy access (CABG) in the treatment of CAD. However, the undisputed benefits of CABG over PCI in various clinical scenarios were recently re-confirmed and subsequently resulted in renewed interest in the development and application of less invasive surgical revascularization procedures. Reports by experienced minimally invasive surgical coronary artery revascularization (MISCAR) centres suggest shortand long-term outcomes that are comparable with conventional CABG and created an exciting platform for further MISCAR innovation while contributing to the global initiation of exciting upcoming MISCAR programs. This manuscript outlines the feasibility, current status and preliminary data of recent advances in contemporary CAD diagnostic-and therapeutic technology, provides and overview of the contemporary CAD revascularization decision-making evidence and describe the future perspectives of MISCAR in an era of rapid advances in less invasive CAD prevention-, diagnostic-and therapeutic technology. We trust that this overview will contribute to future research and changes in clinical practice.

show abstract

“…Off-pump coronary artery bypass surgery (OPCAB) has developed considerably over the past 15 years, 6 especially in Japan. Surveillance by the Japanese Association of Thoracic Surgery in 2007 demonstrated that the 30-day mortality rate of 65% of patients who initially underwent elective CABG as OPCAB to be 0.7%.…”

Section: Coronary Bypass Surgerymentioning

confidence: 99%

Debate over patient-centered care: Percutaneous coronary intervention or coronary artery bypass grafting?

Kawasuji

2011

Surg Today

View full text Add to dashboard Cite

Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) have developed as effective therapies to treat coronary artery disease. Initial CABG is associated with lower mortality than initial medical management, especially among high- and intermediate-risk patients with coronary artery disease. However, PCI is currently the most frequent initial treatment delivered by interventional cardiologists to treat multivessel coronary artery disease, despite substantial evidence from meta-analyses of randomized trials and registry data favoring CABG. Recent advancements in PCI did not result in detectable improvements in death or myocardial infarction compared with medical therapy, although significant reductions in target lesions or vessel revascularization were identified after implantation of a drug-eluting stent (DES) rather than a bare-metal stent. The SYNTAX trial compared patients with left main and/or three-vessel coronary artery disease treated with DES or CABG. The results of the trial demonstrated the 1-year inferiority of PCI compared with CABG with respect to major adverse cardiac and cerebrovascular events. Nevertheless, patients with coronary artery disease continue to receive more recommendations for PCI and fewer for CABG than are indicated in the guidelines. A multidisciplinary team approach should be the standard of care when recommending interventions for treating complex coronary artery disease among patients for whom CABG is superior in terms of survival and freedom from reintervention.

show abstract

Coronary artery bypass grafting without full sternotomy

Cited by 6 publications

References 59 publications

Minimally Invasive Coronary Revascularisation Surgery: A Focused Review of the Available Literature

Minimally Invasive Coronary Revascularisation Surgery: A Focused Review of the Available Literature

Minimally invasive surgical coronary artery revascularization—current status and future perspectives in an era of interventional advances

Debate over patient-centered care: Percutaneous coronary intervention or coronary artery bypass grafting?

Contact Info

Product

Resources

About